NUS · Nu Skin Enterprises, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.49B | $1.73B | $1.97B | $2.23B | $2.70B | $2.58B |
| Cost of Revenue | $453.76M | $550.23M | $611.85M | $630.91M | $675.22M | $658.03M |
| Gross Profit | $1.03B | $1.18B | $1.36B | $1.59B | $2.02B | $1.92B |
| R&D | $10.80M | $13.00M | $22.60M | $23.30M | $27.20M | $23.30M |
| SG&A | $432.14M | $479.04M | $546.86M | $555.77M | $666.39M | $646.85M |
| Total Operating Expenses | $965.63M | $1.33B | $1.31B | $1.48B | $1.79B | $1.67B |
| D&A | $52.26M | $69.81M | $70.92M | $72.51M | $76.32M | $73.99M |
| Operating Income | $65.76M | ($151.59M) | $48.27M | $110.85M | $233.99M | $257.56M |
| Interest Expense | $13.95M | $26.41M | $25.60M | $13.50M | $11.00M | $13.10M |
| Income Tax | $35.99M | ($28.46M) | $17.98M | ($15.81M) | $85.19M | $64.88M |
| Net Income | $160.20M | ($146.59M) | $8.60M | $104.78M | $147.27M | $191.35M |
| EPS - Basic | $3.25 | ($2.95) | $0.17 | $2.10 | $2.93 | $3.66 |
| EPS - Diluted | $3.18 | ($2.95) | $0.17 | $2.07 | $2.86 | $3.63 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $238.63M | $186.88M | $256.06M | $264.73M | $339.59M | $402.68M |
| Accounts Receivable | $39.54M | $50.78M | $72.88M | $47.36M | $41.30M | $63.37M |
| Inventory | $178.64M | $190.24M | $279.98M | $346.18M | $399.93M | $314.37M |
| Accounts Payable | $26.18M | $34.88M | $43.51M | $53.96M | $49.99M | $66.17M |
| Current Assets | $547.70M | $538.60M | $701.87M | $759.87M | $872.95M | $903.20M |
| Total Assets | $1.41B | $1.47B | $1.81B | $1.82B | $1.91B | $1.96B |
| Current Liabilities | $263.73M | $296.61M | $328.87M | $359.24M | $529.69M | $542.86M |
| Long-term Debt | $204.19M | $363.61M | $478.04M | $377.47M | $268.78M | $305.39M |
| Total Liabilities | $600.07M | $817.46M | $984.50M | $923.67M | $993.71M | $1.06B |
| Stockholders' Equity | $805.24M | $651.46M | $821.97M | $897.30M | $912.77M | $894.27M |
| Retained Earnings | $1.86B | $1.71B | $1.87B | $1.94B | $1.91B | $1.84B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $80.29M | $111.74M | $118.64M | $108.06M | $141.58M | $379.14M |
| Investing Cash Flow | $170.66M | ($37.96M) | ($134.50M) | ($67.08M) | ($88.73M) | ($79.43M) |
| Financing Cash Flow | ($202.40M) | ($133.18M) | $10.73M | ($99.50M) | ($104.70M) | ($245.17M) |
| CapEx | $34.28M | $41.58M | $58.49M | $59.06M | $68.61M | $63.82M |
| Free Cash Flow | $46.01M | $70.16M | $60.15M | $49.01M | $72.97M | $315.32M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 69.4% | 68.2% | 68.9% | 71.7% | 75.0% | 74.5% |
| Operating margin | 4.4% | -8.8% | 2.5% | 5.0% | 8.7% | 10.0% |
| EBITDA margin | 7.9% | -4.7% | 6.1% | 8.2% | 11.5% | 12.8% |
| Net margin | 10.8% | -8.5% | 0.4% | 4.7% | 5.5% | 7.4% |
| Free cash flow margin | 3.1% | 4.1% | 3.1% | 2.2% | 2.7% | 12.2% |
| FCF / Net income | 0.29 | -0.48 | 7.00 | 0.47 | 0.50 | 1.65 |
| R&D / Revenue | 0.7% | 0.8% | 1.1% | 1.0% | 1.0% | 0.9% |
| SG&A / Revenue | 29.1% | 27.7% | 27.8% | 25.0% | 24.7% | 25.1% |
| Effective tax rate | 18.3% | - | 67.7% | -17.8% | 36.6% | 25.3% |
| Return on assets | 11.4% | -10.0% | 0.5% | 5.8% | 7.7% | 9.8% |
| Return on equity | 19.9% | -22.5% | 1.0% | 11.7% | 16.1% | 21.4% |
| Return on invested capital | 5.3% | -11.8% | 1.9% | 8.7% | 12.5% | 16.0% |
| Liquidity | ||||||
| Current ratio | 2.08 | 1.82 | 2.13 | 2.12 | 1.65 | 1.66 |
| Quick ratio | 1.40 | 1.17 | 1.28 | 1.15 | 0.89 | 1.08 |
| Cash ratio | 0.90 | 0.63 | 0.78 | 0.74 | 0.64 | 0.74 |
| Leverage | ||||||
| Debt / Equity | 0.25 | 0.56 | 0.58 | 0.42 | 0.29 | 0.34 |
| Debt / Assets | 0.15 | 0.25 | 0.26 | 0.21 | 0.14 | 0.16 |
| Debt / EBITDA | 1.73 | - | 4.01 | 2.06 | 0.87 | 0.92 |
| Interest coverage | 4.7x | -5.7x | 1.9x | 8.2x | 21.3x | 19.7x |
| Equity multiplier | 1.75 | 2.25 | 2.20 | 2.03 | 2.09 | 2.19 |
| Liabilities / Assets | 0.43 | 0.56 | 0.54 | 0.51 | 0.52 | 0.54 |
| Efficiency | ||||||
| Asset turnover | 1.06 | 1.18 | 1.09 | 1.22 | 1.41 | 1.32 |
| Inventory turnover | 2.54 | 2.89 | 2.19 | 1.82 | 1.69 | 2.09 |
| Days sales outstanding | 10d | 11d | 14d | 8d | 6d | 9d |
| Days inventory outstanding | 144d | 126d | 167d | 200d | 216d | 174d |
| Days payable outstanding | 21d | 23d | 26d | 31d | 27d | 37d |
| Cash conversion cycle | 132d | 114d | 155d | 177d | 195d | 147d |
| Valuation | ||||||
| P / E | 3.0x | - | 114.2x | 20.4x | 17.7x | 15.0x |
| P / B | 0.6x | 0.5x | 1.2x | 2.4x | 2.9x | 3.2x |
| P / S | 0.3x | 0.2x | 0.5x | 1.0x | 1.0x | 1.1x |
| EV / EBITDA | 3.8x | - | 10.0x | 12.2x | 8.2x | 8.4x |
| Growth | ||||||
| Revenue growth (YoY) | -14.3% | -12.0% | -11.5% | -17.4% | 4.4% | 6.7% |
| Revenue CAGR (3y) | -12.6% | -13.7% | -8.6% | -2.8% | 6.9% | 4.2% |
| Revenue CAGR (5y) | -10.5% | -6.5% | -2.3% | -0.5% | 4.1% | - |
| Gross profit growth (YoY) | -12.7% | -12.9% | -14.9% | -21.1% | 5.0% | 4.6% |
| Operating income growth (YoY) | - | - | -56.5% | -52.6% | -9.2% | -3.7% |
| Net income growth (YoY) | - | - | -91.8% | -28.9% | -23.0% | 10.3% |
| EPS growth (YoY) | - | - | -91.8% | -27.6% | -21.2% | 17.1% |
| EPS CAGR (3y) | 15.4% | - | -64.0% | -12.6% | 9.8% | 15.4% |
| EPS CAGR (5y) | -2.6% | - | -39.9% | -2.6% | 2.3% | 10.0% |
| FCF growth (YoY) | -34.4% | 16.6% | 22.7% | -32.8% | -76.9% | 181.9% |
| FCF CAGR (5y) | -32.0% | -8.9% | -14.6% | -25.6% | -20.2% | 3.5% |
| Book value growth (YoY) | 23.6% | -20.7% | -8.4% | -1.7% | 2.1% | 2.2% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
3.03
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Comparing NU SKIN ENTERPRISES against the 5 most active filers in the same SIC group.
Dividends
$0.24/share trailing 12 months · 0.0% YoY
| Ex-date | Per share |
|---|---|
| May 29, 2026 | $0.0600 |
| Feb 27, 2026 | $0.0600 |
| Nov 28, 2025 | $0.0600 |
| Aug 29, 2025 | $0.0600 |
| May 30, 2025 | $0.0600 |
| Feb 24, 2025 | $0.0600 |
| Nov 29, 2024 | $0.0600 |
| Aug 30, 2024 | $0.0600 |
| May 31, 2024 | $0.0600 |
| Feb 23, 2024 | $0.0600 |
| Nov 22, 2023 | $0.3900 |
| Aug 24, 2023 | $0.3900 |
| May 25, 2023 | $0.3900 |
| Feb 24, 2023 | $0.3900 |
| Nov 23, 2022 | $0.3850 |
| Aug 25, 2022 | $0.3850 |
| May 26, 2022 | $0.3850 |
| Feb 25, 2022 | $0.3850 |
| Nov 24, 2021 | $0.3800 |
| Aug 26, 2021 | $0.3800 |
| May 27, 2021 | $0.3800 |
| Feb 25, 2021 | $0.3800 |
| Nov 25, 2020 | $0.3750 |
| Aug 27, 2020 | $0.3750 |